Palbocyclibe (Palbociclib)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antineoplastic agents - inhibitors of protein kinases

Included in the formulation
  • Ibrans
    capsules inwards 
    Pfizer Inc.     USA
    • АТХ:

    L.01   Antineoplastic agents

    Pharmacodynamics:

    Selectively inhibits the cyclin-dependent kinases CDK4 and 6, resulting in the restoration of cell cycle control and blocking the proliferation of tumor cells in patients with estrogen-positive / HER2-negative breast cancer.

    Pharmacokinetics:

    After ingestion with meals, up to 46% is absorbed in the gastrointestinal tract. The maximum concentration in the blood plasma is achieved in 6-12 hours. The connection with plasma proteins is 85%.

    Metabolism in the liver.

    The elimination half-life is 29 hours. Elimination with feces and kidneys in the form of metabolites.

    Indications:

    It is used to treat malignant, common, metastatic breast tumors.

    ICD-10

    II.C50.C50   Malignant neoplasm of breast

    Contraindications:

    Severe renal and hepatic impairment, age under 18, pregnancy and lactation, individual intolerance.

    Carefully:

    Dysfunction of the liver of moderate or severe degree, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside with meals, 125 mg once a day for 21 days with a break of 7 days.

    The highest daily dose: 125 mg.

    The highest single dose: 125 mg.

    Side effects:

    Central and peripheral nervous system: fast fatiguability, peripheral neuropathy.

    Respiratory system: pneumonitis - interstitial pulmonary process, dyspnea, rarely - pulmonary embolism.

    Hemopoietic system: neutropenia, leukopenia, thrombocytopenia, anemia.

    The cardiovascular system: palpitations, heart failure, nosebleeds.

    Digestive system: stomatitis, anorexia, diarrhea, nausea, vomiting.

    Dermatological reactions: acne, alopecia, rash.

    Allergic reactions.

    Overdose:

    Acute left ventricular failure.

    Treatment is symptomatic.

    Interaction:

    When used simultaneously with inducers CYP3A4 (carbamazepine, rifampicin, phenytoin), careful monitoring of the patient's condition is recommended to prevent unwanted side reactions.

    Special instructions:

    Monitoring of the blood count, including coagulograms, every 2 weeks during the first two months of treatment, then monthly and according to clinical indications.

    If you miss a dose, take the next dose as soon as possible. The administration of a double dose is once contraindicated.

    It is not recommended to drink the drug with grapefruit juice.

    During treatment, patients need to use reliable contraceptive methods. If the drug causes dizziness, you should stop driving the car and work with moving mechanisms.

    Instructions
    Up